{"id":"NCT03928704","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-25","primaryCompletion":"2022-06-29","completion":"2023-04-17","firstPosted":"2019-04-26","resultsPosted":"2024-11-13","lastUpdate":"2024-11-13"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Nonradiographic Axial Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["BKZ","UCB4940"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).","primaryOutcome":{"measure":"Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo (up to Week 16) (Global Population)","deltaMin":21.4,"sd":null},{"arm":"Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)","deltaMin":47.7,"sd":null},{"arm":"Placebo (up to Week 16) (China Extension Population)","deltaMin":27.3,"sd":null},{"arm":"Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)","deltaMin":33.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":83,"countries":["United States","Belgium","Bulgaria","China","Czechia","France","Germany","Hungary","Japan","Poland","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["36649967","38599650","38834351","39133438","40194794","39406403","37793792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Corona virus infection","Oral candidiasis","Headache"]}}